Abstract-The occurrence of Creutzfeldt-Jakob disease (CJD) among American Indians and Alaska Natives in the United States was evaluated using national multiple cause-of-death data and medical information obtained from state health departments. Twelve CJD deaths were identified for 1981 through 2002, and the average annual age-adjusted death rate was 0.47 per million population. This rate was significantly lower than that for whites and similar to the rate for African Americans. The CJD death rate for whites is higher than for African Americans in the United States, 1 but no reports have examined the occurrence of CJD among the American Indian and Alaska Native (AI/AN) population. This study describes the occurrence of CJD among AI/ANs and compares it with the incidence among whites and African Americans in the United States.
Creutzfeldt-Jakob disease (CJD) has a reported US annual rate of about one case per million. 1 The Centers for Disease Control and Prevention (CDC) conducts surveillance for CJD through several mechanisms including review of national multiple cause-of-death data. 1 Because CJD is fatal generally within a year of diagnosis, death certificate data are useful for CJD surveillance. 1 The National Prion Disease Pathology Surveillance Center (NPDPSC), which was established in 1997 by CDC in collaboration with the American Association of Neuropathologists, augments US surveillance by performing diagnostic testing of suspected CJD patients. 2 The CJD death rate for whites is higher than for African Americans in the United States, 1 but no reports have examined the occurrence of CJD among the American Indian and Alaska Native (AI/AN) population. This study describes the occurrence of CJD among AI/ANs and compares it with the incidence among whites and African Americans in the United States.
Methods. To identify CJD decedents by race, we reviewed the multiple cause-of-death data from the National Center for Health Statistics, CDC, for 1981 through 2002. 3 The data include all deaths occurring in the United States as obtained from death certificates filed by each state. Persons with CJD (sporadic, familial, or iatrogenic) listed as a cause of death anywhere on the record were identified by searching for the International Classification of Diseases (ICD), Ninth Revision code 046.1 for 1981 through 1998 and the ICD-Tenth Revision code A81.0 for 1999 through 2002. 4, 5 Demographic variables such as age, sex, and state of occurrence were analyzed for AI/ANs who had these codes listed. This information was then shared with the appropriate state health departments to obtain death certificates and portions of the medical records for review. Death certificates were used to confirm coding for race and CJD diagnosis, and medical records were evaluated to classify CJD case status based on the World Health Organization (WHO) CJD case definition. 6 To determine whether additional AI/AN CJD cases existed, we reviewed data on patients with available race information who were evaluated at NPDPSC. 2 CJD death rates and age-specific death rates for AI/ANs, whites, and African Americans were calculated using US census estimates for 1981 through 2002. 7 Age-adjusted death rates were standardized by the direct method, using the standard 2000 US population age-group distribution. Poisson regression analysis was used to compare the CJD death rate for AI/ANs with that for whites and for African Americans, taking into account the age distribution of the populations. Results. Twelve CJD deaths were identified among AI/ ANs for 1981 through 2002. Thirteen CJD deaths among AI/ANs were reported; however, we excluded one death that a review of medical records revealed had been coded incorrectly. No additional deaths among AI/ANs were identified through review of NPDPSC data. As determined based on the 12 identified decedents, the average annual age-adjusted CJD death rate during the study period was 0.47 deaths per million population. This rate was lower than the age-adjusted rate for whites (p Ͻ 0.01) and similar to the rate for African Americans (table 1) . Age-specific death rates for AI/ANs, particularly for the 50 to 69-year age group (p Ͻ 0.01), were consistently lower than those for whites.
CJD was listed as the primary cause of death for 10 (83%) of the 12 decedents, and cerebral vascular accident and congestive heart failure were listed as the cause of death for the remaining two decedents. Four decedents (33%) were younger than 55 years of age, and seven (58%) of the decedents were men. The decedents' ages ranged from 39 to 85 years (median 65 years, mean 64.3 years). The 12 deaths occurred in nine states and the District of Columbia.
Death certificate, medical records, or both were obtained for 10 decedents (83%) (table 2). Seven decedents had portions of their medical records available for review. One decedent had an unusually long illness duration (6 years) but met the WHO case definition for probable CJD because of the presence of consistent clinical signs, typical EEG findings, and elevated CSF 14-3-3 protein; no brain tissue or genetic test results were available. All seven decedents had dementia, with typical EEG findings noted for five (71%). In addition, five (71%) had ataxia, four (57%) had myoclonus, and three (43%) had visual disturbances. The median illness duration for seven patients with available information was 7 months (range 2 to 72 months). At Discussion. From 1981 through 2002, 12 CJD deaths occurred among AI/ANs in the United States, for an average annual age-adjusted death rate of 0.47 per million population during the 22-year study period. This rate is significantly lower than the ageadjusted rate of 1.14 per million for whites and is similar to the rate of 0.42 per million for African Americans in the United States for the same period. In addition, the median age at death for AI/AN CJD patients (65 years) was similar to that previously reported for the general US population (68 years). 1 The life expectancy of AI/ANs is almost 4 years less than that for the general US population. 9 This difference may result, at least in part, from barriers to accessing health care services, 9 which could lead to the diagnosis of fewer AI/AN CJD cases. Because CJD is primarily a disease of the elderly, the lower life expectancy could potentially lower the number of CJD deaths that occur among AI/ANs. However, the age-specific CJD death rates were consistently lower among AI/ANs compared to whites, particularly for persons 50 to 69 years of age, indicating that lower life expectancy may not fully explain the difference in CJD death rates.
Multiple cause-of-death data are useful for CJD surveillance in the United States, detecting more than 80% of deaths attributable to CJD. 1 For AI/AN persons identified in the database who died of CJD, we examined available medical records to verify the CJD diagnosis and the patient's race. In these national data, race is determined by the person completing the death certificate; some AI/AN decedents may not have been classified as AI/AN. A study conducted in Washington State found that 87% of Indian Health Service-registered persons with AI/AN ancestry were reported as AI/AN race on the Washington State death certificate; most of the persons with AI/AN ancestry who were not identified as AI/AN were reported as white. 10 However, the study states that the higher the proportion of an individual's American Indian ancestry, the more likely that AI/AN race was reported on the death certificate, and correct classification of AI/AN race was more likely for decedents older than 40 years of age and for persons who did not die of cancer. 10 Although clinical symptoms and disease progression can lead to a probable diagnosis, CJD cannot be confirmed without brain biopsy or autopsy. The autopsy rate of 40% reported in this study highlights the need for increasing awareness of the importance of diagnostic testing. NPDPSC provides state-of-theart testing without charge for suspect TSE cases reported in the United States. 2 This study is the first to examine and describe the occurrence of CJD among AI/ANs in the United States. Although the CJD death rate for AI/ANs was low during the study period, it is important to continue monitoring CJD occurrence among AI/ANs and to submit tissue samples for testing to confirm the diagnosis. 
